Published in the September, 2011 edition of Danish Medical Bulletin, an article by J. Fenger-Grøn et al. titled “Paediatric outcomes following intrauterine exposure to serotonin reuptake inhibitors: a systematic review.” “addresses the potential adverse effects on the foetus and child of maternal SRI medication.” For clarity, “SRI” stands for serotonine reuptake inhibitors, and for our purposes is equivalent to “selective serotonin reuptake inhibitors,” or SSRIs.
This research team states “The literature indicates a slightly increased risk of cardiovascular malformations and persistent pulmonary hypertension of the new-born, while evidence regarding the risk of preterm labour, low birth weight, low Apgar score, prolonged QT interval and miscarriage is less clear” and continues, explaining “An estimated 20-30% of infants will have neonatal symptoms following intrauterine SRI exposure.” (emphasis added)
It is noted that “infants may exhibit neurological, gastrointestinal, autonomic, endocrine or respiratory symptoms. Although the symptoms are self-limited, the families may be seriously affected” and warned that “Until sufficient safety studies have been carried out, SRI must be used with caution in pregnancy and every treatment of the pregnant woman should be thoroughly considered.”
Due to the fact that many SSRI drug manufacturers have failed to provide adequate warning labels that include information on risks for congenital malformations and neonatal adaptation syndrome, a number of SSRI birth defects lawsuits have been filed.
If you or a loved one used SSRIs and gave birth to a child with a congenital malformation or who had neonatal adaptation syndrome, you may be entitled to significant financial compensation. For a free, no-obligation case consultation, contact our team of SSRI birth defect lawyers at the information provided below. We have the experience, resources, and skills required to win the justice you deserve. Call today and see how we can help.
(855) 452 – 5529